Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PHH-1V booster safety and immunogenicity study in adults previously vaccinated against COVID-19
2022-000074-25Phase 3Active
- Sponsor
- HIPRA
- Start
- Jan 2022
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of PHH-1V in coronavirus disease 2019 (COVID-19), sponsored by HIPRA. Primary endpoint: Solicited local reactions through Day 7. Started Jan 2022; status: active.
02
Drugs
PHH-1V
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2022-000074-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-000074-25.